

FOI REF: 23/517

13th September 2023

Tel: 0300 131 4500

Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

Clarification was sought asking you to confirm what you mean by “homecare medicine services provider”, i.e., do you mean any service that would administer medication to a patient in their own home and confirmation was received as follows:

I understand there are two types of homecare services

One is delivery only – but may involve eg refrigerated medicines so have to be delivered direct to the patient’s home.

The other involves staff from the homecare provider administering the meds – eg when they are given as an infusion.

The FoI does distinguish between the two at points but where it does not both should be included in the answer.

East Sussex Healthcare NHS Trust’s ~(ESHT) Pharmacy

- 1) Does your trust employ one or more homecare medicine services provider(s) to deliver and/or administer medicines to patients in their normal residence? If so, what is the name of the provider(s)?**

We have service level agreements with; - Healthnet, Sciensus, Lloyds, Pharmaxo, Fresenius, Personal homecare pharmacy and Alcura.

- 2) For each provider, how many active patients currently receive your homecare medicines service as of 31 July 2023?

HOMECARE PROVIDER	ACTIVE PATIENTS
Sciensus	527
Healthnet	1042
Alcura	202
Lloyds	320
Fresenius	53 (June 2023)
Pharmaxo	3
Personal Homecare Pharmacy	13

- 3) For each provider, how many of these patients are administered medicines as part of the homecare service as of 31 July 2023?

Please see response for Q2, all our patients are on homecare services.

- 4) For each provider, please provide a list of medications delivered and/or administered through this service.

Abrocitinib	Cibinqo	Healthnet
Alirocumab	Praluent	Healthnet
Adalimumab	Humira	Healthnet
Adalimumab	Hyrimoz	Healthnet
Adalimumab	Imraldi	Healthnet
Brodalumab	KYNTHEUM®	Healthnet
Dimethyl Fumarate	Tecfidera	Healthnet
Dupilumab	Dupixent	HealthNet
Erenumab	Aimovig	HealthNet
Filgotinib	Jyseleca	Healthnet
Guselkumab	Tremfya	Healthnet
Infliximab	Remsima	Healthnet
Methotrexate	Metoject	Healthnet
Omalizumab	Xolair	Healthnet
Sarilumab	Kevzara	Healthnet
Risankizumab	Skyrizi	HeathNet
Teriflunomide	Aubagio	HealthNet
Teriperatide	Movymia	Heathnet
Teriperatide	Sondelbay	Heathnet
Tildrakizumab	Ilumetri	HealthNet
Tralokinumab	Adtralza	HealthNet
Upadacitinib	Rinvoq	Healthnet
Ustekinumab	Stelara	HealthNet
Acalabrutinib	Calquence	Alcura
Apremilast	Otezla	Alcura
Certolizumab pegol	Cimzia	Alcura

Fremanezumab	Ajovy	Alcura
Methotrexate	Metoject	Alcura
Palbociclib	Ibrance	Alcura
Adalimumab	Yuflyma	Personal homecare Pharmacy
Evolocumab	Repatha	Fresenius
Abatacept	Orencia	Lloyds
Apremilast	Otezla	LLoyds
Baricitinib	Olumaint	LLoyds
Brodalumab	Kyntheum®	LLoyds
Daclizumab	Zinbryta	LLoyds
Fampridine	Fampyra	Lloyds
Fingolimod	Gilenya	Lloyds
Galcanezumab	Emgality	Lloyds
Glatiramer	Brabio	Lloyds
Glatiramer	Copaxone	LLoyds
Guselkumab	Tremfya	Lloyds
Guselkumab	Tremfya	LLoyds
Interferon - Beta-1a	Avonex	LLoyds
Interferon - Beta-1a	Betaferon	Lloyds
Interferon - Beta-1a	Rebif	Lloyds
Interferon - Beta -1b	Extavia	Lloyds
Peginerferon - Beta 1a	Plegridy	Lloyds
Ixekizumab	Taltz	Lloyds
Ozanimod	Zeposia	Lloyds
Secukinumab	Cosentyx	Lloyds
Teriperatide	Forsteo	LLoyds
Tocilizumab	RoActemra	Lloyds
Trifluridine/tipiracil	Lonsurf	Lloyds
Ustekinumab	Stelara	Lloyds
Certolizumab pegol	Cimzia SELECT	Pharmaxo
Glatiramer	Copaxone	Pharmaxo
Romozozumab	Evenity	Pharmaxo
Abatacept	Orencia	Sciensus
Alirocumab	Praluent	Sciensus
Adalimumab	Amgevita	Sciensus
Adalimumab	Humira	Sciensus
Adalimumab	Imraldi	Sciensus
Apremilast	Otezla	Sciensus
Baricitinib	Olumaint	Sciensus
Certolizumab pegol	Cimzia	Sciensus
Dimethyl Fumarate	Tecfidera	Sciensus
Etanercept	Benepali	Sciensus
Etanercept	Enbrel	Sciensus
Galcanezumab	Emgality	Sciensus

Glatiramer	Copaxone	Sciensus
Golimumab	Simponi	Sciensus
Guselkumab	Tremfya	Sciensus
Interferon - Beta-1a	Avonex	Sciensus
Interferon - Beta-1a	Betaferon	Sciensus
Interferon - Beta-1a	Rebif	Sciensus
Ixekizumab	Taltz (Derm)	Sciensus
Ixekizumab	Taltz (Rheum)	Sciensus
Lanreotide	ADVANZ	Sciensus
Lanreotide	Somatuline	Sciensus
Methotrexate	Metoject	Sciensus
Omalizumab	Xolair	Sciensus
Secukinumab	Cosentyx	Sciensus
Somatropin	Genotropin	Sciensus
Somatropin	Increlex	Sciensus
Somatropin	Norditropin	Sciensus
Somatropin	Nutropin	Sciensus
Somatropin	Omnitrope	Sciensus
Somatropin	Saizen	Sciensus
Somatropin	Zomacton	Sciensus
Tocilizumab	RoActemra	Sciensus
Tofacitinib	Xeljanz	Sciensus
Trastuzimab	Herceptin	Sciensus
Ustekinumab	Stelara	Sciensus
Vedolizumab	Entyvio	Sciensus

- 5) For each provider, how many patient safety incidents were reported in the most recent reporting period for which you have data, and in the comparable reporting periods in 2022 and 2021 (eg if giving figs for July 2023, please also give figs for July 22 and July 21)? Please state what period the figures are for.

HEMOCARE PROVIDER	July 21	July 22	July 23
Sciensus	0	0	3
Healthnet	0	0	2
Alcura	0	1	0
Lloyds	0	0	0
Fresenius	0	0	0
Pharmaxo	0	0	0
Personal Homecare Pharmacy	0	0	0

- 6) For each provider, As a proportion of all deliveries, what percentage of medicine and ancillaries deliveries were late in the most recent reporting period for which you have data, and in the comparable reporting periods in 2022 and 2021 (eg if giving figs for July 2023, please also give figs for July 22 and July 21)? Please state what period the figures are for.

HEMECARE PROVIDER	July 21	July 22	July 23
Sciensus	0	0	2.39%
Healthnet	0	17.76%	14.48%
Alcura	0	3.7%	9.3%
Lloyds	0	2.8%	3.8%
Fresenius	0	0	0
Pharmaxo	0	0	0
Personal Homecare Pharmacy	0	0	0

- 7) For each provider, As a proportion of all deliveries, what percentage of medicine and ancillaries deliveries failed in the most recent reporting period for which you have data, and in the comparable reporting periods in 2022 and 2021 (eg if giving figs for July 2023, please also give figs for July 22 and July 21)? Please state what period the figures are for.

HEMECARE PROVIDER	July 21	July 22	July 23
Sciensus	0	0	4.7%
Healthnet	0	1.87%	1.6%
Alcura	0	2.9%	0
Lloyds	0	1.7%	3.8%
Fresenius	0	0	0
Pharmaxo	0	0	0
Personal Homecare Pharmacy	0	0	0

- 8) For each provider, As a proportion of all clinical services, what percentage of clinical services were late in the most recent reporting period for which you have data, and in the comparable reporting periods in 2022 and 2021 (eg if giving figs for July 2023, please also give figs for July 22 and July 21)? Please state what period the figures are for.

HEMECARE PROVIDER	July 21	July 22	July 23
Sciensus	0	0	40%
Healthnet	0	8.33%	6.52%
Alcura	0	0	0
Lloyds	0	0	0
Fresenius	0	0	0
Pharmaxo	0	0	0
Personal Homecare Pharmacy	0	0	0

- 9) For each provider, what proportion of the KPIs for homecare services did your service meet in in the most recent reporting period for which you have data, and in the comparable reporting periods in 2022 and 2021 (eg if giving figs for July 2023, please also give figs for July 22 and July 21)? Please state what period the figures are for.

Not applicable.

ESHT's Community Health & Integrated Care Division (CHIC)

1. Does your trust employ one or more homecare medicine services provider(s) to deliver and/or administer medicines to patients in their normal residence? If so, what is the name of the provider(s)?

Minerva Nursing

Outsourced Homecare provider that provides social care support to our patients that includes the administration of oral medications only.

2. For each provider, how many active patients currently receive your homecare medicines service as of 31 July 2023?

Not applicable, no delivery services.

3. For each provider, how many of these patients are administered medicines as part of the homecare service as of 31 July 2023?

10 patients had their medication administered as part of the homecare service in the Month of July.

4. For each provider, please provide a list of medications delivered and/or administered through this service.

Administered only:

Accrete D3 tablets
Adcal-D3 chewable tablets
Allopurinol 100mg tablets
Amitriptyline 50mg tablets
Amlodipine 5mg tablets
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler
Apixaban 5mg tablets
Aspirin 75mg dispersible tablets
Atorvastatin 20mg tablets
Atorvastatin 40mg tablets
Atorvastatin 80mg tablets
Bisoprolol 1.25mg tablets
Bisoprolol 2.5mg tablets
Carbocysteine 375mg capsules
Chlorphenamine 4mg tablets

Circadin 2mg modified-release tablets
Clarithromycin 500mg tablets
Colecalciferol 800unit capsules
Diazepam 2mg tablets
Dorzolamide 20mg/ml eye drops
Duloxetine 60mg gastro-resistant capsules
Empagliflozin 25mg tablets
Ezetimibe 10mg tablets
Ferrous sulfate 200mg tablets
Fexofenadine 180mg tablets
Finasteride 5mg tablets
Furosemide 40mg tablets
Gabapentin 100mg capsules
Gabapentin 300mg capsules
Gliclazide 40mgs
Indapamide 1.5mg modified-release tablets
Lansoprazole 30mg gastro-resistant capsules
Latanoprost 50micrograms/ml eye drops 0.2ml unit dose preservative free
Lercanidipine 20mg tablets
Levodopa 175mg / Carbidopa 43.75mg / Entacapone 200mg tablets
Levothyroxine sodium 25microgram tablets
Levothyroxine sodium 50microgram tablets
Linagliptin 5mg tablets
Memantine 10mg tablets
Metformin 1g modified-release tablets
Metformin 500mg modified-release tablets
Metformin 500mg tablets
Metronidazole 400mg tablets
Morphine 10mg modified-release capsules
Omeprazole 20mg gastro-resistant capsules
Paracetamol 500mg caplets PRN
Pioglitazone 45mg tablets
Prochlorperazine 5mg tablets PRN
Ramipril 10mg capsules
Ramipril 5mg capsules
Relvar Ellipta 184micrograms/dose / 22micrograms/dose dry powder inhaler
Risperidone 250microgram tablets
Salamol 100micrograms/dose inhaler CFC free PRN
Simvastatin 40mg tablets
Spironolactone 25mg tablets
Tamsulosin 400microgram modified-release capsules
Thiamine 50mg tablets
Vancomycin 125mg capsules
Zopiclone 7.5mg tablets

5. **For each provider, how many patient safety incidents were reported in the most recent reporting period for which you have data, and in the comparable reporting periods in 2022 and 2021 (eg if giving figs for July 2023, please also give figs for July 22 and July 21)? Please state what period the figures are for.**

July 23 – 0. We did not provide a service in July 2021/2022.

6. For each provider, As a proportion of all deliveries, what percentage of medicine and ancillaries deliveries were late in the most recent reporting period for which you have data), and in the comparable reporting periods in 2022 and 2021 (eg if giving figs for July 2023, please also give figs for July 22 and July 21)? Please state what period the figures are for.

Not applicable, no delivery service.

7. For each provider, As a proportion of all deliveries, what percentage of medicine and ancillaries deliveries failed in the most recent reporting period for which you have data, and in the comparable reporting periods in 2022 and 2021 (eg if giving figs for July 2023, please also give figs for July 22 and July 21)? Please state what period the figures are for.

Not applicable, no delivery service.

8. For each provider, As a proportion of all clinical services, what percentage of clinical services were late in the most recent reporting period for which you have data, and in the comparable reporting periods in 2022 and 2021 (eg if giving figs for July 2023, please also give figs for July 22 and July 21)? Please state what period the figures are for.

0 - No incidents of medications being administered late – Not providing a service July 2021/2022.

9. For each provider, what proportion of the KPIs for homecare services did your service meet in in the most recent reporting period for which you have data, and in the comparable reporting periods in 2022 and 2021 (eg if giving figs for July 2023, please also give figs for July 22 and July 21)? Please state what period the figures are for.

No KPI set for service by the Trust.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Linda Thornhill (Mrs)
Corporate Governance Manager
esh-tr.foi@nhs.net